Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Monsanto And Novartis In Dispute
August 13, 2007
| A version of this story appeared in
Volume 85, Issue 33
Monsanto has filed a $100 million arbitration claim against the Sandoz subsidiary of Novartis for failure to supply all contracted doses of recombinant bovine somatotropin between 2004 and 2006. The Sandoz facility had been the only facility approved by FDA to make the finished formulation of BST used to enhance milk production from cows. However, an FDA inspection of the Sandoz facility in late 2003 led to a warning letter that limited production. Sandoz made corrections, but FDA did not lift its warning letter until 2006.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter